Overview

ASA vs. Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated With Len-Dex Combination Therapy.

Status:
Unknown status

Trial end date:
2021-03-01

Target enrollment:

Participant gender:

Summary

The intended pilot study is designed as a multicenter randomized controlled clinical trial, comparing the impact of two different therapies including ASA vs. Rivaroxaban in newly diagnosed or relapsed and refractory multiple myeloma patients treated with Lenalidomide Dexamethasone (Len-Dex) combination therapy

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Lawson Health Research Institute

Collaborators:

Dalhousie University
Hamilton Health Sciences Corporation
McMaster University
St. Boniface General Hospital Research Centre
St. Boniface Hospital
The Ottawa Hospital

Treatments:

Aspirin
Rivaroxaban